Galapagos NV Company Profile (NASDAQ:GLPG)

About Galapagos NV

Galapagos NV logoGalapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GLPG
  • CUSIP:
Key Metrics:
  • Previous Close: $69.80
  • 50 Day Moving Average: $67.28
  • 200 Day Moving Average: $61.66
  • 52-Week Range: $39.63 - $73.37
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -40.11
  • P/E Growth: 0.00
  • Market Cap: $3.22B
  • Beta: 1.85
Profitability:
  • Net Margins: -67.15%
  • Return on Equity: -8.23%
  • Return on Assets: -5.78%
Debt:
  • Current Ratio: 7.42%
  • Quick Ratio: 7.42%
Additional Links:
Companies Related to Galapagos NV:

Analyst Ratings

Consensus Ratings for Galapagos NV (NASDAQ:GLPG) (?)
Ratings Breakdown: 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $66.50 (4.73% downside)

Analysts' Ratings History for Galapagos NV (NASDAQ:GLPG)
Show:
DateFirmActionRatingPrice TargetDetails
1/5/2017Stifel NicolausInitiated CoverageHold$65.00View Rating Details
12/23/2016Cowen and CompanyReiterated RatingBuyView Rating Details
10/18/2016Goldman Sachs Group, Inc. (The)UpgradeNeutral -> BuyView Rating Details
8/30/2016Janney Montgomery ScottInitiated CoverageBuy -> Buy$64.00View Rating Details
6/17/2016Credit Suisse GroupReiterated RatingHold$48.00View Rating Details
5/2/2016Morgan StanleyReiterated RatingBuy$89.00View Rating Details
12/17/2015Bryan, Garnier & CoBoost Price TargetBuy$52.00 -> $64.00View Rating Details
12/8/2015KBC SecuritiesUpgradeBuyView Rating Details
6/8/2015NomuraInitiated CoverageBuy$73.00View Rating Details
(Data available from 2/21/2015 forward)

Earnings

Earnings History for Galapagos NV (NASDAQ:GLPG)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Galapagos NV (NASDAQ:GLPG)
Current Year EPS Consensus Estimate: $-0.03 EPS
Next Year EPS Consensus Estimate: $-1.74 EPS

Dividends

Dividend History for Galapagos NV (NASDAQ:GLPG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Galapagos NV (NASDAQ:GLPG)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Galapagos NV (NASDAQ:GLPG)
DateHeadline
News IconGalapagos NV GLPG Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:GLPG)
www.bioportfolio.com - February 19 at 10:37 AM
realistinvestor.com logoGalapagos NV (ADR) (NASDAQ:GLPG) EPS Projection At $-0.825 - RealistInvestor.com (NASDAQ:GLPG)
www.realistinvestor.com - February 4 at 3:56 AM
us.rd.yahoo.com logo4:03 pm Galapagos NV announces dosing of the first patient with cystic fibrosis Class III with novel CF corrector GLPG2222 as an add-on to Kalydeco; announces the opening of an Investigational New Drug file with the US Food & Drug Administr (NASDAQ:GLPG)
us.rd.yahoo.com - February 3 at 10:55 PM
gurufocus.com logoGalapagos NV Tests Cystic Fibrosis Treatment on First Patient ... - GuruFocus.com (NASDAQ:GLPG)
www.gurufocus.com - February 3 at 5:54 PM
streetinsider.com logoGalapagos NV (GLPG) Doses First CF Patient with GLPG2222 - StreetInsider.com (NASDAQ:GLPG)
www.streetinsider.com - February 3 at 5:54 PM
finance.yahoo.com logoGalapagos NV Tests Cystic Fibrosis Treatment on First Patient (NASDAQ:GLPG)
finance.yahoo.com - February 3 at 5:54 PM
seekingalpha.com logoDosing underway in Galapagos' mid-study study of CF candidate GLPG2222 (NASDAQ:GLPG)
seekingalpha.com - February 2 at 6:03 PM
streetinsider.com logoGalapagos NV (GLPG) Doses First CF Patient with GLPG2222 (NASDAQ:GLPG)
www.streetinsider.com - February 2 at 4:18 AM
us.rd.yahoo.com logoGalapagos doses first patient with novel CF corrector GLPG2222 (NASDAQ:GLPG)
us.rd.yahoo.com - February 1 at 6:09 PM
News IconStock Dragged Lower Ahead of Market Open: Galapagos NV (NASDAQ:GLPG) - Aiken Advocate (NASDAQ:GLPG)
aikenadvocate.com - January 31 at 4:19 AM
News IconShares of Galapagos NV (GLPG) Sees Large Outflow of Money ... - Highland Mirror (NASDAQ:GLPG)
www.highlandmirror.com - January 30 at 6:07 PM
News IconTrading Watch: ADX and CCI Review for Galapagos Nv Sp ADR (GLPG) - Springdale Times (NASDAQ:GLPG)
springdaletimes.com - January 26 at 6:55 PM
News IconGalapagos NV (ADR) (NASDAQ:GLPG) to Post $0.22 Earnings Per Share: Analysts - Wall Street Beacon (NASDAQ:GLPG)
wsbeacon.com - January 26 at 6:55 PM
News IconGalapagos NV (NASDAQ:GLPG) Updated Broker Ratings - NewsDen - NewsDen (NASDAQ:GLPG)
newsden.net - January 25 at 4:16 AM
News Icon2016 Industry Pressures Drive Mixed Healthcare Investor Sentiment in 4th Quarter (NASDAQ:GLPG)
www.cbs58.com - January 24 at 6:08 PM
globenewswire.com logoGalapagos creates new warrant plan - GlobeNewswire (press release) (NASDAQ:GLPG)
globenewswire.com - January 20 at 11:47 PM
finance.yahoo.com logoGalapagos creates new warrant plan (NASDAQ:GLPG)
finance.yahoo.com - January 20 at 6:45 PM
seekingalpha.com logoGilead: I'm Sorry (But It's Even Better Than I Thought) (NASDAQ:GLPG)
seekingalpha.com - January 19 at 7:11 PM
4-traders.com logoGalapagos : Dr. Walid Abi-Saab joins Galapagos as Chief Medical Officer (NASDAQ:GLPG)
www.4-traders.com - January 19 at 7:11 PM
News IconStock Backsliding Ahead of the Bell, Gapping Down: Galapagos NV (NASDAQ:GLPG) - Aiken Advocate (NASDAQ:GLPG)
aikenadvocate.com - January 19 at 3:57 AM
finance.yahoo.com logo4:01 pm Galapagos NV names Dr. Walid Abi-Saab as Chief Medical Officer effective March 1 (NASDAQ:GLPG)
finance.yahoo.com - January 17 at 8:26 PM
finance.yahoo.com logoDr. Walid Abi-Saab joins Galapagos as Chief Medical Officer (NASDAQ:GLPG)
finance.yahoo.com - January 17 at 8:26 PM
realistinvestor.com logoGalapagos NV (ADR) (NASDAQ:GLPG) EPS Estimate At $-0.825 - RealistInvestor.com (NASDAQ:GLPG)
www.realistinvestor.com - January 14 at 10:30 PM
investing.com logoBelgium stocks lower at close of trade; BEL 20 down 0.34% (NASDAQ:GLPG)
www.investing.com - January 11 at 6:02 PM
News IconGalapagos NV GLPG Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:GLPG)
www.bioportfolio.com - January 7 at 11:52 PM
marketexclusive.com logoAnalyst Activity – Stifel Nicolaus Initiates Coverage On Galapagos NV (NASDAQ:GLPG) With a Hold (NASDAQ:GLPG)
marketexclusive.com - January 5 at 6:23 PM
News IconImportant Rating: Galapagos NV (NASDAQ:GLPG) Is Now Covered By Stifel. What to Expect? (NASDAQ:GLPG)
www.whatsonthorold.com - January 5 at 6:23 PM
finance.yahoo.com logoCoverage initiated on Galapagos NV by Stifel (NASDAQ:GLPG)
finance.yahoo.com - January 5 at 6:23 PM
finance.yahoo.com logoWhy Galapagos (GLPG) Could Be Positioned for a Surge? (NASDAQ:GLPG)
finance.yahoo.com - December 29 at 5:32 PM
finance.yahoo.com logoGalapagos NV Announces Results From Cystic Fibrosis Treatment Study (NASDAQ:GLPG)
finance.yahoo.com - December 27 at 5:34 PM
marketexclusive.com logoAnalyst Activity – Cowen and Company Reiterates Buy on Galapagos NV (NASDAQ:GLPG) (NASDAQ:GLPG)
marketexclusive.com - December 25 at 5:05 PM
marketexclusive.com logoAnalyst Activity – Cowen and Company Reiterates Buy on ... - Market Exclusive (NASDAQ:GLPG)
marketexclusive.com - December 25 at 10:53 AM
marketexclusive.com logoAnalyst Activity – Cowen and Company Reiterates Buy on Galapagos NV (NASDAQ:GLPG) - Market Exclusive (NASDAQ:GLPG)
marketexclusive.com - December 24 at 5:13 PM
realistinvestor.com logoGalapagos NV (ADR) (NASDAQ:GLPG) EPS Prediction At $-0.23 - RealistInvestor.com (NASDAQ:GLPG)
www.realistinvestor.com - December 23 at 10:45 PM
4-traders.com logoGalapagos : SAPHIRA 1 topline shows competitive clinical results in G551D patients (NASDAQ:GLPG)
www.4-traders.com - December 21 at 6:20 PM
streetinsider.com logoGalapagos NV (GLPG) SAPHIRA 1 Phase 2 Study Shows Competitive Clinical Results (NASDAQ:GLPG)
www.streetinsider.com - December 21 at 6:20 PM
seekingalpha.com logoGalapagos's CF candidate GLPG1837 shows positive effect in mid-stage study; shares up 3% (NASDAQ:GLPG)
seekingalpha.com - December 21 at 6:20 PM
streetinsider.com logoGalapagos NV (GLPG) SAPHIRA 1 Phase 2 Study Shows ... - StreetInsider.com (NASDAQ:GLPG)
www.streetinsider.com - December 21 at 5:26 AM
publicnow.com logoSAPHIRA 1 topline shows competitive clinical results in G551D patients (NASDAQ:GLPG)
www.publicnow.com - December 21 at 5:26 AM
News IconGalapagos NV (NASDAQ:GLPG) Analyst Recommendation - NewsDen (NASDAQ:GLPG)
newsden.net - December 17 at 4:01 AM
4-traders.com logoGalapagos : The Lancet publishes FITZROY study results with filgotinib in Crohn's disease (NASDAQ:GLPG)
www.4-traders.com - December 15 at 11:05 PM
us.rd.yahoo.com logoThe Lancet publishes FITZROY study results with filgotinib in Crohn's disease (NASDAQ:GLPG)
us.rd.yahoo.com - December 15 at 6:03 PM
insidermonkey.com logoHedge Funds Are Betting On Galapagos NV (ADR) (GLPG) (NASDAQ:GLPG)
www.insidermonkey.com - December 14 at 2:02 AM
seekingalpha.com logoDosing underway in Gilead's late-stage study of filgotinib in ulcerative colitis (NASDAQ:GLPG)
seekingalpha.com - December 12 at 11:28 AM
News IconGalapagos: Start Phase 2b/3 study with filgotinib in ulcerative colitis (NASDAQ:GLPG)
www.pressreleasepoint.com - December 9 at 5:40 PM
rttnews.com logoFOLD Slowly Unfolding, EBS Continues Contract Spree, HZNP Plunges On Trial Data (NASDAQ:GLPG)
www.rttnews.com - December 9 at 10:13 AM
streetinsider.com logoGalapagos NV (GLPG) Commences Dosing in SELECTION Phase 2b/3; Milestone Payment Triggered (NASDAQ:GLPG)
www.streetinsider.com - December 9 at 10:13 AM
finanznachrichten.de logoGalapagos NV: Start Phase 2b/3 study with filgotinib in ulcerative colitis (NASDAQ:GLPG)
www.finanznachrichten.de - December 8 at 6:04 PM
finance.yahoo.com logoStart Phase 2b/3 study with filgotinib in ulcerative colitis (NASDAQ:GLPG)
finance.yahoo.com - December 8 at 6:04 PM
finanznachrichten.de logoGalapagos NV: Galapagos increases share capital through warrant exercises (NASDAQ:GLPG)
www.finanznachrichten.de - November 30 at 5:32 PM

Social

What is Galapagos NV's stock symbol?

Galapagos NV trades on the NASDAQ under the ticker symbol "GLPG."

Where is Galapagos NV's stock going? Where will Galapagos NV's stock price be in 2017?

6 brokers have issued twelve-month price objectives for Galapagos NV's shares. Their forecasts range from $48.00 to $89.00. On average, they expect Galapagos NV's stock price to reach $66.50 in the next year.

What are analysts saying about Galapagos NV stock?

Here are some recent quotes from research analysts about Galapagos NV stock:

  • According to Zacks Investment Research, "Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. " (1/31/2017)

  • Cowen and Company analysts commented, "Galapagos reported positive data from the SAPHIRA1 trial of GLPG1837 in G551D CF." (12/23/2016)

  • Janney Montgomery Scott analysts commented, "interesting paradigm" in the management of Rheumatoid Arthritis (RA). Thus, in Filgotinib (partnered with Gilead), Galapagos has a "potential blockbuster."The Filgotinib Advantage"We are modeling peak sales of $1.9 billion for filgotinib in RA, and $658 million in Crohn's with Ulcerative Colitis offers additional optionality (not in our FV)," analyst Debjit Chattopadhyay wrote in a note.Chattopadhyay acknowledges that Filgotinib is at least two years behind Baricitinib, an RA drug from Incyte Corporation (NASDAQ: INCY) and Eli Lilly and Co (NYSE: LLY).Related Link: Here Are All The Big Biotech Mergers In 2016However, since the company's drug is third in to launch, it may be a commercial positive, because experience from Pfizer Inc. (NYSE: PFE)'s Xeljanz suggests physicians are likely to become increasingly more comfortable with the safety profile of JAK inhibitors over the next two years."Filgotinib JAK1 specificity resulting in a superior hematologic safety profile over competitors could be an advantage (more so in IBD); oral dosing increases convenience over biologics; and although experience with GILD suggests otherwise, filgotinib could be priced attractively vs. other JAK's and biosimilars (we are modeling a $21,000 launch price in U.S.)," Chattopadhyay noted.Cystic FibrosisMeanwhile, the analyst highlighted that Cystic Fibrosis corrector/potentiator commercial opportunity could exceed $7 billion globally, and he assumes a 30 percent market share for Galapagos/AbbVie.Currently, Vertex is the leader in Cystic Fibrosis market with its Kalydeco and Orkambi. The analyst noted that with about 70,000 patient commercial opportunities, it may not be feasible for Galapagos to develop a potentiator and corrector sequentially, especially if Vertex's triple-combo succeeds in meaningfully improving upon Orkambi."Whether GLPG/ABBV will choose a phase 3 program prior to a triple-combo phase 2 is not yet clear, but will likely be data dependent. Either way, progress on the CF program will be a key driver of sentiment on GLPG stock over the next 12 to 18 months, in our view," (8/30/2016)

Who owns Galapagos NV stock?

Galapagos NV's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (10.02%), Federated Investors Inc. PA (2.39%), EcoR1 Capital LLC (1.22%), Deerfield Management Co. (0.92%), Perceptive Advisors LLC (0.66%) and Orbimed Advisors LLC (0.61%).

Who sold Galapagos NV stock? Who is selling Galapagos NV stock?

Galapagos NV's stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC and Clough Capital Partners L P.

Who bought Galapagos NV stock? Who is buying Galapagos NV stock?

Galapagos NV's stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Renaissance Technologies LLC, EcoR1 Capital LLC, Employees Retirement System of Texas, FMR LLC, Castleark Management LLC and Marshall Wace LLP.

How do I buy Galapagos NV stock?

Shares of Galapagos NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Galapagos NV stock cost?

One share of Galapagos NV stock can currently be purchased for approximately $69.80.

Galapagos NV (NASDAQ:GLPG) Chart for Tuesday, February, 21, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Galapagos NV (NASDAQ:GLPG)

Earnings History Chart

Earnings by Quarter for Galapagos NV (NASDAQ:GLPG)

Dividend History Chart

Dividend Payments by Quarter for Galapagos NV (NASDAQ:GLPG)

Last Updated on 2/21/2017 by MarketBeat.com Staff